In our arthritis model, we found an increased expression of β-arrestin and GRK2 in chondrocytes, but β2-AR agonist when administered at disease onset throughout the course of study, inhibited β-arrestin and GRK2 expression (Figure 10). Here, GRK2 is linked to arthritic joint disease.